Stockscreener 앱 받기
6.08
5.00%
-0.32
Gyre Therapeutics Inc 주식(GYRE)의 최신 뉴스
GYRE Q2 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesTax Rate Impact - dars.gov.et
Gyre Therapeutics stock posts double digit 12 month gain as investors watch pipeline progress - AD HOC NEWS
Solid Biosciences (Nasdaq:SLDB)Stock Analysis - Simply Wall Street
Gyre Therapeutics stock holds steady as investors await next clinical and earnings milestones - AD HOC NEWS
Gyre Therapeutics, Inc.Common Stock (Nasdaq:GYRE) Detailed Stock Data - The Chronicle-Journal
Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Exploring a 159.98% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Gyre Therapeutics, Inc.Common Stock (Nasdaq:GYRE) Stock Quote - The Chronicle-Journal
Gyre Therapeutics Q2 2026 Earnings: Wider-Than-Expected Loss, Yet Shares Rise 6.57%EBITDA Margin Trends - www.dars.gov.et
Gyre Therapeutics to Participate in Upcoming September Investor Conferences - The Manila Times
Gyre Therapeutics to Participate in Upcoming September Investor Conferences - marketscreener.com
Two live online healthcare talks will feature Gyre Therapeutics this month - Stock Titan
Gyre Therapeutics Highlights Capital-Efficient Global Development Strategy - The Globe and Mail
Gyre Therapeutics Highlights Capital-Efficient Global Development Strategy - TipRanks
Gyre updates corporate presentation, outlines China-driven R&D and F351 regulatory progress - TradingView
Gyre Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Gyre Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Gyre Therapeutics unveils capital-efficient global development strategy - The Globe and Mail
Gyre Therapeutics unveils capital-efficient global development strategy - TipRanks
Gyre Therapeutics posts updated corporate presentation detailing pipeline progress and China-commercial revenue drivers - TradingView
Gyre (GYRE) Results Review: The EPS Result Is Below Expectation in the Latest Session; After Results: Shares Move 1.82% Down for the Current SessionBalance Sheet Strength - vinanet.vn
Gyre (GYRE): Slides 2.10% to $7.00 in Latest Trading; Trading Range: Price Remains Between $6.65 Support and $7.35 ResistanceBackspread Trade - vinanet.vn
Gyre Therapeutics (NASDAQ:GYRE) Lowered to "Strong Sell" Rating by Zacks Research - MarketBeat
Palomar (PLMR) Results Check: EPS Clears the Reported Estimate in the Latest Session; Market Response: Shares Move 0.92% LowerMargin Improvement Report - careplusvn.com
Gyre (GYRE): Slides 2.10% to $7.00 in Latest Trading; Trading Range: Price Remains Between $6.65 Support and $7.35 ResistanceMedian Line - siam.in
Analysts Set Expectations for GYRE Q3 Earnings - MarketBeat
GYRE | Gyre Therapeutics, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Claire Weston Net Worth (2026) - GuruFocus
Analysts Are Bullish on These Healthcare Stocks: Gyre Therapeutics (GYRE), Align Tech (ALGN) - The Globe and Mail
Noble Financial Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Gyre Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Gyre Therapeutics Inc (GYRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Gyre Therapeutics earnings missed by $0.06, revenue topped estimates - Investing.com Nigeria
GYRE Q1 2026 Earnings: Narrower-Than-Expected Loss Lights a Fire Under SharesEarnings Surprise Score - vinanet.vn
Gyre Therapeutics (NASDAQ:GYRE) Issues Earnings Results - MarketBeat
Gyre Therapeutics earnings missed by $0.06, revenue topped estimates - Investing.com Canada
Form 8K Gyre Therapeutics Inc For: 7 August By Investing.com - Investing.com Nigeria
GYRE: Net loss widened to $32.8 million on $53.5 million revenue, with strong liquidity maintained - TradingView
Gyre Therapeutics (NASDAQ: GYRE) swings to 32,849 H1 2026 net loss - Stock Titan
Gyre Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
H.C. Wainwright Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Gyre Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Gyre Therapeutics Q2 EPS misses estimate despite sales beat - scanx.trade
Gyre Therapeutics, Inc. expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Gyre Therapeutics Sees 2026 Rev $100.5M-$111.0M >GYRE - Moomoo
Gyre Therapeutics Reports Second Quarter 2026 - Moomoo
Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Form 8K Gyre Therapeutics Inc For: 7 August By Investing.com - Investing.com Canada
GYRE Q2 Revenue Falls To $29.1 Million As Net Loss Widens - Quiver Quantitative
GYRE: Q2 2026 revenue reached $29.1M, net loss widened, and Cullgen acquisition expanded the pipeline - TradingView
Gyre Therapeutics reports Q2 2026 revenue $29.1M, GAAP EPS $(0.12); full-year revenue guidance affirmed - TradingView
5.28%
자본화:
|
볼륨(24시간):